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Introduction
Decision-making with patients with incurable cancer is be-
coming increasingly complex and is often surrounded by med-
ical uncertainty. When considering treatment, it is often un-
clear whether the potential benefits of treatment outweigh its 
risks and side effects. Tumor-specific therapy can potentially 
prolong life, but, due to its toxicity, may considerably reduce 
quality of life. Hence, decisions about cancer-specific therapy 
often require trade-offs between quality of life (QL) and 
length of life (LL). Evaluations of such trade-offs may vary 
considerably. Some patients accept treatments despite high re-
ported toxicities and uncertain outcomes in order to increase 
their chances of prolonging survival. Others prioritize QL 
over LL [1, 2]. Thus, a prerequisite for patient-oriented deci-
sion-making is the understanding of patient preferences and 
their timely integration into patient care [3]. However, the 
identification of patients’ views remains difficult in clinical 
practice. Evaluation of patients’ preferences is an important 
quality parameter for clinical care. There is a need for a stand-
ardized assessment in all research fields that should be in-
formed by patients’ preferences: palliative care research, 
health services research, and research on shared decision-
making. Most previous research on decision-making has fo-
cused on either assessment of health-related quality of life 
(HRQoL) or the evaluation of the utility of therapeutic op-
tions (i.e., standard gamble, time trade-off, and the visual 
analog scale) [1, 4]. These methods are directed at concrete 
therapeutic decisions and cannot be used to elicit patients’ 
general attitudes. In contrast, the ‘Quality and Quantity Ques-
Keywords
Cancer patients’ preferences · Oncology · Quality of life
Summary
Background: Decision-making with patients with incura-
ble cancer often requires trade-offs between quality and 
length of life. The ‘Quality and Quantity Questionnaire’ 
(QQ) is an English-language measure of patients’ prefer-
ence for length or quality of life. The aim of this study 
was to translate and validate this questionnaire. Materi-
als and Methods: 1 new item was formulated to improve 
the ‘Quality of life’ scale. Construct validity including ex-
ploratory factor analysis, convergent and discriminant 
validity, and reliability was determined in n = 194 pa-
tients. Results: The acceptability of the questionnaire 
among patients was high. The item-non-response rate 
was very low (2.5–4%). The 2 QQ scales ‘Quality of life’ 
(QL) and ‘Length of life’ (LL) had good and acceptable 
internal consistency (Cronbach’s = 0.71 for LL and 0.59 
for QL). Convergent validity was shown by significant 
correlation of the QL subscale with the CCAT (Cancer 
Communication Assessment Tool) subscale ‘Limitation 
of treatment’ (r = 0.37, p < 0.01) and the LL scale with the 
CCAT subscale ‘Continuing treatment’ (r = 0.24, p = 0.00). 
Conclusion: The German version of ‘QQ’ has satisfactory 
psychometric properties for measuring patients’ prefer-
ences for LL or QL. It can be used in all research fields 
that should be informed by patients’ preferences: shared 
decision-making, palliative care, and health services.
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them think about their dire prognosis. Finally, after evaluating the results 
of this pre-test, the questionnaire was modified once more based on sug-
gestions from the patients. As a main change, a new item was added in 
order to include a stronger representation of balancing life span and qual-
ity of life: ‘If it is doubtful whether I can extend my life with a burden-
some treatment, then I would rather choose a treatment that places a spe-
cial emphasis on quality of life’ (Item 9).
Instruments
Socio-demographic data and health status (cancer diagnosis and stage, 
illness duration, and prognosis as estimated by the attending physician) 
were collected. Additionally, QL patient preferences in the decision-mak-
ing process, cancer-related psychosocial distress, and satisfaction with re-
lationships were assessed with the following established instruments.
Health-Related Quality of Life
HRQoL in cancer patients was assessed with a multidimensional can-
cer-specific instrument, namely the Functional Assessment of Cancer 
Therapy-General (FACT-G) [7]. The sum score of the subscales (physical 
well-being, social/family well-being, emotional well-being, functional well-
being) was used. Low FACT values indicate a low quality of life. We sup-
posed that quality of life and patients’ preferences for LL or QL are 
unrelated. 
Patient Preferences
The Cancer Communication Assessment Tool for Patients (CCAT-P) 
assesses patients’ values and preferences regarding treatment and care 
decisions with an emphasis on the family’s role in the decision-making 
process [8]. A modified German version of this instrument has been vali-
dated, and demonstrated acceptable reliability and validity [9]. It consists 
of 12 items on the following 4 subscales: ‘Disclosure’ (5 items,  = 0.66), 
‘Limitation of treatment’ (3 items,  = 0.51), ‘Family involvement in treat-
ment decisions’ (2 items,  = 0.68), and ‘Continuing treatment’ (2 items, 
= 0.51). 2 subscales of this instrument reflect a trade-off between QL and 
LL, namely the subscales ‘Limitation of treatment’ and ‘Continuing treat-
ment’. We expected a positive correlation between the subscale ‘Limita-
tion of treatment’ and the QL subscale, and a positive correlation be-
tween ‘Continuing treatment’ and the LL subscale.
Psychosocial Distress
Psychosocial distress was assessed with a 10-item screening instrument 
for self-assessment of psychosocial distress in cancer patients, namely the 
Questionnaire on Stress in Cancer Patients (QSC-R10) [10]. We expected 
that psychological distress and patients’ preferences for LL or QL are 
unrelated. 
Relationship Satisfaction 
Relationship satisfaction was assessed with an adapted version of the 
Positive and Negative Quality in Marriage Scale (PANQIMS) [11]. 
2 items were used to measure the satisfaction with the relationship re-
garding both positive and negative qualities, using an 11-point scale rang-
ing from ‘0 = not at all’ to ‘10 = extremely’. We hypothesized that satisfac-
tion with relationship has an impact on patients’ preferences.
Statistical Analysis
The acceptability of the questionnaire was assessed by calculating the 
percentage of missing data per item. Item analysis included assessment of 
the distribution of the responses in order to determine floor and ceiling 
effects. In this study, we refer to floor and ceiling effects if more than 15% 
tionnaire’ (QQ) is a tool for directly assessing a patient’s gen-
eral preference for LL or QL. It was developed for different 
groups of cancer patients in the Netherlands by Stiggelbout, 
de Haes, Kiebert, Kievet, and Leer (1996), and has shown 
good psychometric properties [2]. However, in German-
speaking countries, there is no comparable instrument for as-
sessing trade-offs between QL and LL. Therefore, the aim of 
this study was to translate the QQ into German, and study its 




To validate the German version of the QQ, patients with different 
types of tumors were recruited at the National Center for Tumor Diseases 
and the Thorax Clinic of the University of Heidelberg. Exclusion criteria 
for participation were a lack of proficiency in the German language, cog-
nitive impairment, or lacking the capacity to consent. The study was ap-
proved by the institutional review board of the University of Heidelberg. 
Consecutive series of patients were enrolled in the study. Out of 298 pa-
tients screened for eligibility, 252 fulfilled the inclusion criteria and were 
asked to participate in the study. 223 patients agreed to participate, 29 
(11%) declined. Of the 223 distributed questionnaires, 198 (89%) were 
returned. 4 questionnaires were incomplete; these were excluded from 
further analysis. The final sample included 194 patients (77% of the pa-
tients approached). 
Validation Procedure
Quality and Quantity Questionnaire
The original version of the QQ consists of 8 items in 2 preference di-
mensions: QL and LL. Patients indicate how strongly they agree or disa-
gree with a statement on a 5-point Likert scale. High scores on the quan-
tity or quality scale indicate the importance of LL or QL, respectively. The 
original questionnaire showed adequate reliability; Cronbach’s alphas 
were 0.68 for the QL scale and 0.79 for the LL scale.
Translating of the Quality and Quantity Questionnaire
Using the guidelines for the intercultural adaptation of measuring in-
struments [5], the QQ was translated by an interdisciplinary team (includ-
ing a sociologist, psychologists, an oncologist, and an independent profes-
sional translator). 2 team members (K.L. and H.S.) independently trans-
lated the original version of the QQ into German. The translated versions 
were merged by discussion and consensus within the research team. Then, 
it was translated back into English by an independent professional trans-
lator. The team reviewed the synthesized translated version, and approval 
was obtained from the author of the original questionnaire.
Cognitive Pre-Test
In order to learn how the translated questionnaire was interpreted and 
understood by the patients, a pre-test was conducted with oncology inpa-
tients (n = 10) at the University Hospital of Heidelberg [6]. It encom-
passed cognitive techniques including paraphrasing, thinking aloud, and 
asking questions to clarify unclear ideas. The majority of participants felt 
the questionnaire was clear. However, it was noticed that some items were 
too generally phrased and referred to abstract ideas such as ‘normal life’ 
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on the QL, unlike the original version. However, it was re-
tained in the QL factor due to content reasons. Cronbach’s 
alpha coefficient was used to assess internal consistency;  = 
0.71 was observed for LL and  = 0.59 for quality of life. The 
extent to which each item was representative of the full scale 
was calculated using the coefficients of item discrimination. 
The discriminability of the single items ranged between Rit = 
0.28 (Item 6) and Rit = 0.61 (Item 8). These Rit are middle-rate 
of the interviewees have chosen the smallest lowest (floor effect) or big-
gest highest (ceiling effect) answer category, respectively. The discrimina-
tion power of items was examined using the coefficients of item 
discrimination.
Measure of sampling adequacy (MSA) was assessed by analysis of the 
anti-image correlation matrix. Variables which have MSA values of less 
than 0.50 should be excluded from the factor analysis. 
Principal component analysis with varimax rotation was used to exam-
ine the factorial structure of the translated version. Items were included 
in the analysis with a factor loading above 0.30 on the factor. The explora-
tory factor analysis was chosen to reveal new structure as 1 additional 
newly formulated item was added. The internal consistency of the trans-
lated QQ was evaluated for each dimension using Cronbach’s alpha 
coefficient. 
Convergent validity, which means that the tested instrument correlates 
with other instruments measuring theoretically similar constructs, was as-
sessed by Pearson’s correlation with the 2 subscales of the CCAT-P. Dis-
criminant validity, the comparison of the QQ with other instruments 
measuring different constructs, was assessed by correlations between the 
QQ subscales and the measures of psychosocial distress and HRQoL. The 
association between socio-demographic variables, health status, QL and 
LL were additionally explored using parametric tests (t-tests and one-way 
ANOVAs) or Pearson’s correlation coefficients. All analyses were per-
formed using SAS software, version 9.3 (SAS Institute Inc., Cary, NC, 
USA). Statistical significance was set for all comparisons at p < 0.05 
(two-tailed).
Results
Socio-Demographic and Disease-Related Characteristics of 
the Sample
The distribution of socio-demographic and disease-related 
characteristics is displayed in table 1.
Item Analyses
Acceptability of the questionnaire was investigated with 
the calculation of the percentage of missing values for each 
item. This item-non-response rate was very low (2.5–4%). The 
items with the highest number of missing values were Item 4 
(n = 8; 4%) and Item 5 (n = 8; 4%).
Factor Analysis and Reliability
MSA was used to ensure adequacy of sampling. The MSA 
values for all the individual items were > 0.60 which ensured 
the suitability of each item for factor analysis (table 2). Ex-
ploratory factor analysis was carried out using the principle 
component method with varimax rotation. The factor analysis 
revealed 2 factors with an eigenvalue of > 1 which explained 
49.9% of the total variance. The factor loads varied from 0.32 
to 0.77. All items, with the exception of Item 5, had loads 
greater than 0.50 on the accompanying factor, which can be 
considered high loadings. Item 5 showed a low loading of 0.32 
Table 1. Socio-demographic and disease-related characteristics of the 
sample (n =194)
Age




Female  62 (32)




No  25 (12.9)




No  24 (12.4)
Unknown   0
Education, n (%)
Total 185 
< 9 years  81 (43.8)
> 9 years 104 (56.2)
Unknown   0
Employment
Total 194
Currently working  20 (10.3)





Unknown   0
Duration of illness
Total, n 191
Mean (SD, median), years   2.89 (5.0, 1.2)
Unknown   3
Disease stage at assessment, n (%)
I–III  34 (17.5)
IV 145 (74.8)
Unclear  15 (7.7)




No  34 (17.5)
Unclear  15 (7.7)
Unknown   0
Tumor type, n (%)
Lung  63 (32.5)
Kidney  28 (14.4)
Prostatic  19 (9.8)
Colon  18 (9.3)
Rectum  15 (7.7)
Pancreatic  14 (7.2)
Bladder  12 (6.2)
Others  25 (12.9)
Unknown   0
Estimated prognosis, n (%)
Total 192
< 6 months  38 (19.8)
6–12 months  59 (30.7)
> 12 months  95 (49.5)
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Convergent Validity
The CCAT subscale ‘Limitation of treatment’ was highly 
positively correlated with the QL subscale (r = 0.37; p = 0.01) 
and negatively correlated with the LL subscale (r = –0.23; p = 
0.01). The subscale ‘Continuing treatment’ was positively cor-
related with the LL (r = 0.24; p = 0.00). Contrary to our expec-
tation, ‘Continuing treatment’ did not show a negative corre-
lation with QL. The role of the family in decision-making 
about cancer treatment was correlated with the choice for LL 
(r = 0.17; p = 0.01). Those who valued their family’s input in 
cancer treatment decisions and involved their family in the 
decision-making process showed a stronger tendency to 
choose LL. The correlation coefficients of QQ subscales with 
patients’ preferences are shown in supplemental table 3.
Discriminant Validity
To evaluate the discriminant validity of the translated QQ, 
we correlated it with different psychometric measures 
(HRQoL and psychosocial distress). There was no significant 
relationship between patients’ self-reported HRQoL and the 
subscales of the translated QQ (LL r = 0.04; p = 0.73 and QL r 
= 0.02; p = 0.74). Also, psychosocial distress did not correlate 
substantially with any of the subscales (LL r = 0.05; p = 0.52 
and QL r = 0.01; p = 0.90).
[12]. The Pearson’s correlation between the 2 subscales was r 
= –0.25, p = 0.00. In table 2, item and scale descriptive statisti-
cal values of the QQ are shown.
Associations with Socio-Demographic and Disease-Related 
Variables
A comparison of means (t-test) was used to assess the as-
sociation of the translated QQ subscales with gender, partner-
ship, children, and educational level. No significant differences 
were found for either subscale for gender, children, educa-
tional level and partner, contrary to our expectations. The 
variables employment and prognosis had 3 levels. Hence, one-
way ANOVAs were carried out. A significant difference ap-
peared concerning the preferences for QL between the groups 
by employment (working: mean = 3.0, on sick leave: mean = 
3.4, unemployed: mean = 3.5; p = .01). The group of patients 
who were not employed had higher levels on the quality scale. 
No significant difference was found between prognosis and 
the 2 subscales. As expected, the LL subscale and satisfaction 
with partnership (considering positive aspects of partnership 
(r = 0.17; p = 0.027) and negative aspects (r = 0.16; p = 0.043)) 
were slightly but significantly correlated. A Pearson’s correla-
tion analysis showed no significant association between the 
subscales of the translated QQ and patient age as well as du-
ration of illness. The relationship with socio-demographic and 
disease-related variables is presented in supplemental table 3. 











Factor 1: Length of life (LL) 3.15 0.71 30.2%
Q8. In order to live a bit longer, I would clutch at any straw. 0.77 3.0 ± 1.4 3 0.58a 0.61 0.72
Q7. I would always accept a hard to tolerate treatment,  
even if the chance of it prolonging my life was as little as 1%.
0.76 2.3 ± 1.4 2 0.61 0.57 0.74
Q1. If a treatment could prolong my life, I would always  
accept it, whatever the side effects might be.
0.74 3.4 ± 1.0 3 0.64 0.52 0.79
Q3. If I reached a point during treatment at which I felt  
like giving up, I would probably manage to find the strength  
to continue.
0.57 3.86 ± 0.9 4 0.74 0.33 0.74
Factor 2: Quality of life (QL) 3.51 0.59 19.7%
Q6. If I had to endure 6 months of intensive treatment in  
order to live for an extra half year, then I wouldn’t bother.
0.68 3.07 ± 1.3 3 0.56 0.28 0.64
Q9. If it is doubtful whether I can extend my life with a  
burdensome treatment, then I would rather choose a treatment 
that places a special emphasis on the quality of life.
0.67 3.8 ± 0.9 3 0.54 0.34 0.72
Q2. If a life-prolonging treatment would prevent me from  
leading a normal life, then I would rather not have it.
0.62 3.7 ± 1.1 4 0.54 0.32 0.61
Q4. I can imagine some side effects being so bad that I would  
refuse the treatment, even if that meant a shorter life.
0.51 3.4 ± 1.0 3 0.47 0.45 0.75
Q5. A moment might come at which I would say ‘I have done  
my best, this is the limit’.
0.32 3.46 ± 1.3 4 0.54 0.31 0.79
aAlpha if item deleted.
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Discussion
Assessment of patients’ preferences for LL or QL in ad-
vanced cancer is essential for all fields of research that focus 
on decision-making and on patients’ needs and goals. For this 
purpose, the QQ was translated into German, and psychomet-
ric properties were assessed in this study.
The factor validity of the LL scale was replicated, although 
the QL scale was not as robust. The LL factor was character-
ized by high loads (0.57–0.77). While Item 5 (‘Es kann ein Mo-
ment kommen, an dem ich sage: Ich habe mein Bestes getan, 
ich kann nicht mehr’) loaded substantially less on the QL in 
comparison with the original study, it was still assigned to the 
QL factor. 
An examination of reliability showed good results for the 
LL subscale (0.71). The reliability of the original question-
naire was somewhat higher (0.79). For the QL, Cronbach’s 
alpha was not as good (0.59) but still acceptable: Cronbach’s 
alpha values of 0.5–0.7 are generally considered as an accept-
able level of internal consistency. Without the new item, how-
ever, it was only 0.54, so we decided to retain the new item. 
The slightly lower reliability and factorial validity found for 
the QL subscale compared to the original study might be ex-
plained by variations in interpreting the quality of life concept 
among the interviewed patients. The pre-test of the translated 
questionnaire indicated that participants had more questions 
and comments about the QL subscale. It was often pointed 
out that Item 5 was formulated too generally. Future studies 
should be conducted for further evaluation of the QL 
subscale.
Furthermore, the pre-test showed that some patients felt 
distressed while answering the questions. Similar observations 
were reported in the original study [4]. We would therefore 
advice to use this questionnaire together with an offer of an 
additional consultation or psycho-oncological counseling.
The German version of the QQ had few significant associa-
tions with socio-demographic or disease-related variables. 
Only employment status and the QL subscale were positively 
associated. Unemployed patients (predominantly pensioners) 
tended to prefer QL. The other correlation found in the origi-
nal study was between LL and having children. This connec-
tion could not be found in our study, but there was a signifi-
cant relation between family role in decision-making and 
striving for LL (p = 0.01). Furthermore, satisfaction with part-
nership was also associated with striving for LL. This confirms 
the validity of the questionnaire, assuming that people wish to 
stay alive for their partners.
In contrast to the original study [2] and the studies con-
ducted by Vogt et al. [13] and Rietjens et al. [3], we found no 
correlation between patients’ age and preferences for either 
QL or LL in our study population. In accordance with the 
original study, there was no correlation between prognosis 
and preference for LL or QL. In our study, it was not clear 
whether the patients were aware of their survival prognosis. 
Future studies should focus on the influence of the survival 
prognosis as perceived by patients on preference for LL or 
QL.
Limitations of the Study
We could not perform test-retest (reliability) measure-
ments due to the cross-sectional design of the study. The sam-
ple did not include many young patients, which could have re-
sulted in a lack of association between age and preference for 
LL or QL. Similarly, our sample included only 20% of far-ad-
vanced cancer patients with an estimated medium survival of 
< 6 months. No difference between estimated prognosis and 
patients’ preferences was revealed. However, larger studies 
are necessary in order to assess whether prognosis may be a 
mediator in the choice between LL and QL. 
Conclusion
The QQ was translated and validated in the present study, 
and psychometric results indicated that the German transla-
tion had satisfactory reliability and validity and can be used in 
studies with German-speaking populations. The translated 
QQ (supplemental fig. 1) can be used for further empirical 
studies of patient preferences and to improve therapeutic 
treatment decisions by integrating patient preferences accord-
ing to QQ results into decisions about the intensity of treat-
ment [14].
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